Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong Soo | - |
dc.contributor.author | Kim, Min Ja | - |
dc.contributor.author | Cha, Sung-Ho | - |
dc.contributor.author | Kim, Hwang Min | - |
dc.contributor.author | Kim, Jong-Hyun | - |
dc.contributor.author | Kim, Kwang Nam | - |
dc.contributor.author | Lee, Jin-Soo | - |
dc.contributor.author | Choi, Jun Yong | - |
dc.contributor.author | Castells, Valerie Bosch | - |
dc.contributor.author | Kim, Hee Soo | - |
dc.contributor.author | Bang, Joon | - |
dc.contributor.author | Oster, Philipp | - |
dc.date.accessioned | 2021-09-04T00:55:08Z | - |
dc.date.available | 2021-09-04T00:55:08Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 1201-9712 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88997 | - |
dc.description.abstract | Objectives: To assess the safety and immunogenicity of a meningococcal polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) in a Korean population. Methods: This was a phase III, blind-observer, controlled study in which participants aged 11-55 years were randomized (2: 1 ratio) to a single dose of MenACYW-D or tetanus/diphtheria/acellular pertussis (Tdap) vaccine. Outcomes included rates of seroconversion against all serogroups (>= 4-fold increase in antibody titer from pre-vaccination), geometric mean titers (GMTs) at days 0 and 28 based on a serum bactericidal assay using baby rabbit complement, rates of seroprotection (titer >= 1: 128) at day 28, and safety. Results: A total of 300 participants were enrolled in the study (200 MenACYW-D and 100 Tdap). Seroconversion rates for serogroups A, C, Y, and W-135 were 77.8%, 88.3%, 74.6%, and 92.4%, respectively, for the MenACYW-D group and 9.3%, 8.1%, 12.2%, and 8.2%, respectively, for the Tdap group. The proportions of participants with pre-vaccination titers >= 1: 128 were 57.3%, 12.6%, 51.5%, and 22.2% for serogroups A, C, Y, and W-135, respectively; post-vaccination rates were 98.5%, 89.4%, 96.0%, and 95.0% for the MenACYW-D group. A lower proportion of participants reported solicited reactions with MenACYW-D (46.2%) compared with Tdap (76.8%). Conclusion: A single dose of MenACYW-D was well tolerated and elicited a robust immune response in Korean adolescents and adults. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | IMMUNE MEMORY | - |
dc.subject | DISEASE | - |
dc.title | Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Min Ja | - |
dc.identifier.doi | 10.1016/j.ijid.2016.02.010 | - |
dc.identifier.scopusid | 2-s2.0-84960474180 | - |
dc.identifier.wosid | 000374877300011 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, v.45, pp.59 - 64 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.title | INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | - |
dc.citation.volume | 45 | - |
dc.citation.startPage | 59 | - |
dc.citation.endPage | 64 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | IMMUNE MEMORY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | Meningococcal vaccine | - |
dc.subject.keywordAuthor | MenACYW-D | - |
dc.subject.keywordAuthor | Immunogenicity | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Republic of Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.